Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-95437446
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JNJ-95437446 is an investigational **antibody-drug conjugate** being developed for the treatment of advanced-stage solid tumors, including advanced colorectal cancer. As an antibody-drug conjugate (ADC), JNJ-95437446 consists of a monoclonal antibody linked to a cytotoxic payload, allowing for targeted delivery of the toxic agent directly to cancer cells. The drug is currently being studied in a Phase 1 clinical trial to evaluate its safety, side effects, and establish recommended Phase 2 doses in adults with advanced colorectal and other solid tumors. The precise molecular target and cytotoxic payload for JNJ-95437446 have not been publicly disclosed as of now. JNJ-95437446 is developed by Johnson & Johnson[1][3][5][7].
Beyond the preview
Go deeper on JNJ-95437446.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-95437446.